PORTLAND, IA, UNITED STATES, January 9, 2025 /EINPresswire / -- The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and enhance the global network.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

World's Most Comprehensive Protein Study Highlights Ultima's Commitment to Unlocking the Power of Genomics at Scale FREMONT, Calif., Jan. 9, 2025 ...

Human Metapneumovirus (HMPV) primarily spreads through respiratory secretions from coughing or sneezing, close personal ...

Vietnam RNAi Therapeutics Market Key Takeaways: The Vietnam RNAi Therapeutics market is undergoing robust growth, fueled by factors such as advancements in RNA interference (RNAi) technology, a ...

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators ...

On January 8, 2025, the Department of Justice (“DOJ”) published its Final Rule to implement President Biden’s Executive Order 14117, ...